Transplant Diagnostics Market

Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Global Forecast to 2028

Report Code: MD 4870 Apr, 2023, by marketsandmarkets.com

Updated on : April 10, 2023

The global transplant diagnostics market in terms of revenue was estimated to be worth $4.4 billion in 2022 and is poised to grow at a CAGR of 7.4% from 2022 to 2028.

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increased impact of infectious diseases. The number of people with end-stage organ failure has been rising, and due to advancements in transplantation, a larger percentage of  people are now eligible for organ transplantation. This growing need is a result of these two factors. Increasing public and private funding for transplantation and various organ transplant awareness campaigns.

Global Transplant Diagnostic Market

Transplant Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Transplant Diagnostics Market

e- Estimated; p- Projected

Transplant Diagnostics Market Dynamics

Drivers: Increasing number of transplant procedures.

The rising adoption of several technologies and screening tests, genomic profiling and cross-matching are making transplants a suitable way of giving life or rebirth of the individual. The rising number of transplant procedures across major countries can be attributed to the rising CAGR of the transplant market. For instance, in the U.S 41,354 organ transplants were carried out in 2021, France 5,273 organ transplants in 2021. Diseases such as TB, end-stage renal diseases and liver cirrhosis are common among geriatric individuals and it makes it a compulsion for the individual to undergo transplant surgery.

Opportunities: Growing public awareness about organ donation and transplantation.

In 2022, the American Transplant foundation organized a fundraising event namely DLA Awards to support programs that promote public awareness related to organ donations and transplantations In 2021, the Organ receiving and giving awareness network (India) conducted an awareness program that aimed to strengthen public willingness to donate organs for transplantation procedures in India.In US long runs of 3kms,5kms and 10kms are organized to promote organ transplants within the public and make them aware of the necessity of giving life to others.

Challenges: Significant gap between number of organs donors and organs required.

There is a significant gap between number of organs donated annually and number of organs donations required. The limited number of organs donated annually across the globe is primarily due to strict government enforcement and limited medical reimbursements for living organ donors and lack of awareness about organ donations.

Restraints: High procedural cost of NGS and PCR-based diagnostic assays

Transplant diagnostic procedures for Histocompatibility tests,blood profiling,genomic profiling are conducted through specialized molecular diagnostic platforms that consists of several advanced technologies. These technologies are integrated with conventional PCR/NGS instruments and thus the cost of these advanced products is on the higher edge.

Market Ecosystem

Transplant Diagnostics Market Ecosystem

By technology, the molecular assay technologies segment accounted for the largest share of the transplant diagnostics market during the forecast period.

In 2022, molecular assay technologies accounted for the largest share of in the market. This segment is projected to reach USD 6,156.9 million in 2028 from USD 4,166.0 in 2022, at a CAGR of 8.0% during the forecast period. Molecular assays are used in transplant diagnostic procedures for donor-recipient compatibility testing. The growing demand for molecular assays during transplant diagnostic procedures is mainly attributed to the technological benefits offered by these assays as compared to non-molecular assays, such as high procedural efficacy, the study of multiple samples and real time analysis.

By End User, Independent reference laboratories is expected to grow at the fastest rate in the transplant diagnostics market during the forecast period.

In 2022, Independent reference laboratories hold a larger share In the market with a share of 58.65%. This end-user segment is projected to reach USD 4,233.9 in 2028 from USD 2,668.8 in 2022. This end-user segment is also expected to grow at the highest CAGR of 8.0% during the forecast period. The large share of this segment can be attributed to the rapid modernization and automation of diagnostic laboratories and growing number of research and developmental activities.

By Product & Services, the Reagents & Consumables segment holds the largest share of the transplant diagnostics market.

In 2022, Reagents & Consumables holds the largest around 72.2% in the market. This Product & Service segment is projected to reach USD 5,131.0 million in 2028 from USD 3,265.2 million in 2022. Reagents & consumables account for the largest share of transplant diagnostics. Expansion in the application horizons of molecular assay techniques in transplant diagnostics, increasing patient emphasis on effective and early patient profiling during organ transplantation.

By Application, Infectious disease testing accounted for the largest share of the transplant diagnostics market during the forecast period.

In 2022, Infectious disease testing is projected to reach USD 3,764.3 million in 2028 from USD 2,344.0 million in 2022.A number of factors, such as ongoing technological advancements in the field of molecular assay techniques, the increasing adoption of these techniques for pathogen detection and histocompatibility testing and the rising incidence of infectious chronic diseases is helping this segment to grow at a high CAGR.

North America is expected to be the largest region in the transplant diagnostics market during the forecast period.

North America, comprising the US and Canada, accounted for the largest share of 45.4% of the market in 2022. Factors such as the high prevalence of diseases, the rising geriatric population, emergence of infectious diseases is contributing to the large share of North America.

APAC region is growing at the highest CAGR of 8.3% due to increasing organ donations and various public and private reimbursements policies.

Transplant Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2021, prominent players in the market are include bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US) among others.

Transplant Diagnostics Market Report Scope:

Report Metric

Details

Market size available for years

2020–2028

Base year considered

2021

Forecast period

2022–2028

Forecast units

Value (USD)

Segments covered

Technology, Product & Service, Application, Transplant type, End User & Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Companies covered

include bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), RMerck KGaA (US),

This report categorizes the global transplant diagnostics market into following segments & sub-segments:

By Technology

  • Molecular assay technologies
    • PCR-based molecular assays
    • Real-time PCR
    • Sequence-specific primer-PCR
    • Sequence-specific Oligonucleotide-PCR
    • Other PCR-based molecular assays
  • Sequencing based molecular assays
    • Sanger sequencing
    • Next generation sequencing
    • Other sequencing based molecular assays
  • Non molecular assays technologies

By Product & Service

  • Reagents & Consumables
  • Instruments
  • Software & Services

By Application

  • Diagnostic application
    • Pre-transplantation Diagnostics
      • Infectious Disease testing
      • Histocompatibility testing
      • Blood profiling
    • Post -transplantation Diagnostics
  • Research applications

By transplant type

  • Solid Organ Transplantation
    • Kidney transplantation
    • Liver transplantation
    • Heart transplantation
    • Lung transplantation
    • Pancrease transplantation
    • Other Organs transplantation
  • Stem Cell transplantation
  • Soft tissue transplantation
  • Bone marrow transplantation

By End User

  • Hospitals and Transplant centers
  • Research &Academic Institutes
  • Independent reference laboratories

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In February 2023, BD received FDA approval for BD Onclarity HPV assay in the serology testing segment
  • In March 2023 BioRad received AQAC International and AFNOR approval for its iQ-Check kits.
  • Hoffmann-La Roche Ltd. unveiled Cobas Infinity edge, a cloud-based point-of-care platform that is available everywhere, in January 2022. Practitioners in the healthcare industry can manage patient data thanks to advanced technology. This has aided the business in diversifying its product offering.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN: TRANSPLANT DIAGNOSTICS MARKET
           2.1.1 SECONDARY DATA
                    FIGURE 2 KEY DATA FROM SECONDARY SOURCES
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                    2.1.2.3 Breakdown of primaries
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 6 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
           2.3.1 METHODOLOGY-RELATED LIMITATIONS
    2.4 RISK ASSESSMENT 
          TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
 
3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 8 REAGENTS & CONSUMABLES TO CONTINUE TO DOMINATE TRANSPLANT DIAGNOSTICS MARKET UNTIL 2028
    FIGURE 9 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR SEGMENT DOMINATED MARKET IN 2022
    FIGURE 10 KIDNEY TRANSPLANTATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    FIGURE 11 INFECTIOUS DISEASE TESTING SEGMENT TO DOMINATE TRANSPLANT DIAGNOSTIC APPLICATIONS MARKET BY 2028
    FIGURE 12 INDEPENDENT REFERENCE LABORATORIES TO DOMINATE MARKET DURING FORECAST PERIOD
    FIGURE 13 REGIONAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 55)
    4.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 14 RISING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET
    4.2 MARKET, BY TECHNOLOGY, 2022 VS. 2028 (USD MILLION) 
          FIGURE 15 PCR-BASED MOLECULAR ASSAYS TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.3 ASIA PACIFIC: MARKET SHARE, BY END USER AND COUNTRY (2022) 
          FIGURE 16 INDEPENDENT REFERENCE LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 MARKET, BY TRANSPLANT TYPE, 2022 VS. 2028 (USD MILLION) 
          FIGURE 17 HEART TRANSPLANTATION SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 MARKET, BY COUNTRY 
          FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 60)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing number of transplant procedures
                    5.2.1.2 Technological advancements in transplant diagnostic procedures
                    5.2.1.3 Increasing public-private funding for target research activities
                                TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR DEVELOPMENT OF TRANSPLANT DIAGNOSTIC PRODUCTS, 2018–2022
                    5.2.1.4 Rising prevalence of infectious diseases
           5.2.2 RESTRAINTS
                    5.2.2.1 High procedural cost of NGS- and PCR-based diagnostic assays
                                TABLE 3 EUROPE: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS (2021)
                    5.2.2.2 Limited reimbursement for target procedures
                                TABLE 4 US: MEDICAL REIMBURSEMENTS FOR TRANSPLANTATION PROCEDURES (2021)
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation
                    5.2.3.2 Growing public awareness about organ donation and transplantation
           5.2.4 CHALLENGES
                    5.2.4.1 Significant gap between number of organ donors and organs required annually
                    5.2.4.2 Procedural and technical limitations associated with donor-recipient screening
    5.3 IMPACT OF RECESSION ON MARKET 
 
6 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 68)
    6.1 INTRODUCTION 
          TABLE 5 MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
           6.1.1 MOLECULAR ASSAY TECHNOLOGIES
                    TABLE 6 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2020–2028 (USD MILLION)
                    TABLE 7 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                    TABLE 8 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020–2028 (USD MILLION)
                    TABLE 9 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020–2028 (USD MILLION)
                    TABLE 10 MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020–2028 (USD MILLION)
                    6.1.1.1 PCR-BASED MOLECULAR ASSAYS
                                TABLE 11 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                TABLE 12 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                                TABLE 13 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 14 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2020–2028 (USD MILLION)
                                TABLE 15 MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.1.1 Sequence-specific oligonucleotide-PCR
                                             6.1.1.1.1.1 Most widely adopted technique in PCR-based molecular assays market
                                                              TABLE 16 MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.1.2 Sequence-specific primer-PCR
                                             6.1.1.1.2.1 Growing public-private investments for research activities to support market growth
                                                              TABLE 17 MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.1.3 Real-time PCR
                                             6.1.1.1.3.1 Requires smaller sample volume compared to conventional PCR technologies
                                                              TABLE 18 MARKET FOR REAL-TIME PCR, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.1.4 Other PCR-based molecular assays
                                              TABLE 19 MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION)
                    6.1.1.2 SEQUENCING-BASED MOLECULAR ASSAYS
                                TABLE 20 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                TABLE 21 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                                TABLE 22 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 23 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2020–2028 (USD MILLION)
                                TABLE 24 MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.2.1 Sanger sequencing
                                             6.1.1.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market
                                                              TABLE 25 MARKET FOR SANGER SEQUENCING, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.2.2 Next-generation sequencing
                                             6.1.1.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS
                                                              TABLE 26 MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020–2028 (USD MILLION)
                               6.1.1.2.3 Other sequencing-based molecular assays
                                              TABLE 27 MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020–2028 (USD MILLION)
           6.1.2 NON-MOLECULAR ASSAY TECHNOLOGIES
                    6.1.2.1 Replacement of non-molecular assay techniques with DNA-based techniques to hamper growth
                                TABLE 28 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                                TABLE 29 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 30 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020–2028 (USD MILLION)
                                TABLE 31 MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020–2028 (USD MILLION)
 
7 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 87)
    7.1 INTRODUCTION 
          TABLE 32 MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
           7.1.1 REAGENTS & CONSUMABLES
                    7.1.1.1 Largest and fastest-growing segment of market
                                TABLE 33 MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2020–2028 (USD MILLION)
           7.1.2 INSTRUMENTS
                    7.1.2.1 Increasing public-private investments to drive market
                                TABLE 34 MARKET FOR INSTRUMENTS, BY REGION, 2020–2028 (USD MILLION)
           7.1.3 SOFTWARE & SERVICES
                    7.1.3.1 Growing automation & digitalization of diagnostic laboratory procedures to support market growth
                                TABLE 35 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2020–2028 (USD MILLION)
 
8 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 92)
    8.1 INTRODUCTION 
          TABLE 36 MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
           8.1.1 DIAGNOSTIC APPLICATIONS
                    TABLE 37 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION)
                    TABLE 38 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
                    8.1.1.1 Pre-transplantation diagnostics
                                TABLE 39 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY TYPE, 2020–2028 (USD MILLION)
                                TABLE 40 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020–2028 (USD MILLION)
                               8.1.1.1.1 Infectious disease testing
                                             8.1.1.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market
                                                              TABLE 41 INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2020–2028 (USD MILLION)
                               8.1.1.1.2 Histocompatibility testing
                                             8.1.1.1.2.1 Technological advancements and growing R&D activities to propel market
                                                              TABLE 42 HISTOCOMPATIBILITY TESTING MARKET, BY REGION, 2020–2028 (USD MILLION)
                               8.1.1.1.3 Blood profiling
                                             8.1.1.1.3.1 Growing availability of molecular assay products to support market growth
                                                              TABLE 43 BLOOD PROFILING MARKET, BY REGION, 2020–2028 (USD MILLION)
                    8.1.1.2 Post-transplantation diagnostics
                               8.1.1.2.1 Greater risk of disorders and infections post-transplantation makes diagnostics necessary step
                                              TABLE 44 POST-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020–2028 (USD MILLION)
           8.1.2 RESEARCH APPLICATIONS
                    8.1.2.1 Growing funding for research to drive market
                                 TABLE 45 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
 
9 TRANSPLANT DIAGNOSTICS MARKET, BY END USER (Page No. - 100)
    9.1 INTRODUCTION 
          TABLE 46 MARKET, BY END USER, 2020–2028 (USD MILLION)
           9.1.1 INDEPENDENT REFERENCE LABORATORIES
                    9.1.1.1 Rising consolidation of diagnostic laboratories to drive market
                                TABLE 47 MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2020–2028 (USD MILLION)
           9.1.2 HOSPITALS & TRANSPLANT CENTERS
                    9.1.2.1 Growing purchasing power of hospitals & transplant centers to support market growth
                                TABLE 48 MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2020–2028 (USD MILLION)
           9.1.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
                    9.1.3.1 Increasing industry-academia collaborations in genomics-based transplant diagnostic research to drive market
                                TABLE 49 MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2020–2028 (USD MILLION)
 
10 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE (Page No. - 105)
     10.1 INTRODUCTION 
             TABLE 50 MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
             10.1.1 SOLID ORGAN TRANSPLANTATION
                        TABLE 51 SOLID ORGAN TRANSPLANTATION MARKET, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 52 SOLID ORGAN TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.1 Kidney transplantation
                                     10.1.1.1.1 Rising prevalence of kidney diseases to drive market
                                                      FIGURE 20 NUMBER OF KIDNEY TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
                                                      TABLE 53 KIDNEY TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.2 Liver transplantation
                                     10.1.1.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market
                                                      FIGURE 21 NUMBER OF LIVER TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
                                                      TABLE 54 LIVER TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.3 Lung transplantation
                                     10.1.1.3.1 Rising prevalence of chronic lung diseases to drive market
                                                      FIGURE 22 NUMBER OF LUNG TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
                                                      TABLE 55 LUNG TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.4 Heart transplantation
                                     10.1.1.4.1 Increasing prevalence of chronic cardiac diseases to propel market
                                                      FIGURE 23 NUMBER OF HEART TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
                                                      TABLE 56 HEART TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.5 Pancreas transplantation
                                     10.1.1.5.1 Procedural complexity and risk of surgical complications to restrain growth
                                                      FIGURE 24 NUMBER OF PANCREAS TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028
                                                      TABLE 57 PANCREAS TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
                        10.1.1.6 Other organ transplantation
                                      TABLE 58 OTHER ORGAN TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
             10.1.2 STEM CELL TRANSPLANTATION
                        10.1.2.1 Rising procedural volume and growing research activities to drive market
                                      TABLE 59 STEM CELL TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
             10.1.3 SOFT TISSUE TRANSPLANTATION
                        10.1.3.1 Technological advancements and rising prevalence of target diseases to drive market
                                      TABLE 60 SOFT TISSUE TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
             10.1.4 BONE MARROW TRANSPLANTATION
                        10.1.4.1 Dearth of well-trained surgeons to perform bone marrow transplantation to hinder growth
                                      TABLE 61 BONE MARROW TRANSPLANTATION MARKET, BY REGION, 2020–2028 (USD MILLION)
 
11 TRANSPLANT DIAGNOSTICS MARKET, BY REGION (Page No. - 118)
     11.1 INTRODUCTION 
             TABLE 62 MARKET, BY REGION, 2020–2028 (USD MILLION)
             11.1.1 NORTH AMERICA
                        FIGURE 25 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 63 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
                        TABLE 64 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                        TABLE 65 NORTH AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 66 NORTH AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 67 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                        TABLE 68 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                        TABLE 69 NORTH AMERICA: MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
                        TABLE 70 NORTH AMERICA: MARKET, BY END USER, 2020–2028 (USD MILLION)
                        11.1.1.1 US
                                     11.1.1.1.1 Technological advancements in transplant diagnostics to drive market
                                                      FIGURE 26 US: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021
                                                      TABLE 71 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 72 US: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 73 US: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.1.2 Canada
                                     11.1.1.2.1 Growing availability of transplant diagnostic products to support market growth
                                                      FIGURE 27 CANADA: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021
                                                      TABLE 74 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 75 CANADA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 76 CANADA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
             11.1.2 EUROPE
                        TABLE 77 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
                        TABLE 78 EUROPE: MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                        TABLE 79 EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 80 EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 81 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                        TABLE 82 EUROPE: MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                        TABLE 83 EUROPE: MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
                        TABLE 84 EUROPE: MARKET, BY END USER, 2020–2028 (USD MILLION)
                        11.1.2.1 GERMANY
                                     11.1.2.1.1 Largest market for transplant diagnostics in Europe
                                                      TABLE 85 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 86 GERMANY: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 87 GERMANY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.2.2 UK
                                     11.1.2.2.1 Rising number of transplantation procedures to drive market
                                                      TABLE 88 UK: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
                                                      TABLE 89 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 90 UK: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 91 UK: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.2.3 France
                                     11.1.2.3.1 Increased adoption of molecular diagnostic techniques for donor-recipient compatibility testing to propel market
                                                      TABLE 92 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 93 FRANCE: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 94 FRANCE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.2.4 Spain
                                     11.1.2.4.1 Rising number of solid organ transplantation procedures to drive market
                                                      TABLE 95 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 96 SPAIN: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 97 SPAIN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.2.5 Italy
                                     11.1.2.5.1 Sluggish growth in healthcare sector to restrain market growth
                                                      TABLE 98 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 99 ITALY: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 100 ITALY: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.2.6 Rest of Europe
                                      TABLE 101 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                      TABLE 102 REST OF EUROPE: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                      TABLE 103 REST OF EUROPE: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
             11.1.3 ASIA PACIFIC
                        FIGURE 28 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 104 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
                        TABLE 105 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                        TABLE 106 ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 107 ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 108 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                        TABLE 109 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                        TABLE 110 ASIA PACIFIC: MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
                        TABLE 111 ASIA PACIFIC: MARKET, BY END USER, 2020–2028 (USD MILLION)
                        11.1.3.1 China
                                     11.1.3.1.1 Improvements in healthcare infrastructure to support market growth
                                                      TABLE 112 CHINA: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
                                                      TABLE 113 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 114 CHINA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 115 CHINA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.3.2 India
                                     11.1.3.2.1 Increasing number of transplantation procedures to drive market
                                                      TABLE 116 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 117 INDIA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 118 INDIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.3.3 Japan
                                     11.1.3.3.1 Rising prevalence of chronic diseases to support market growth
                                                      FIGURE 29 JAPAN: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019–2021
                                                      TABLE 119 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 120 JAPAN: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 121 JAPAN: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.3.4 Australia
                                     11.1.3.4.1 Rising number of solid organ transplantation procedures to drive market
                                                      TABLE 122 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 123 AUSTRALIA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 124 AUSTRALIA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.3.5 South Korea
                                     11.1.3.5.1 Government initiatives to introduce medical coverage for transplantation to drive market
                                                      TABLE 125 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 126 SOUTH KOREA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 127 SOUTH KOREA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.3.6 Rest of Asia Pacific
                                      TABLE 128 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                      TABLE 129 REST OF ASIA PACIFIC: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                      TABLE 130 REST OF ASIA PACIFIC: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
             11.1.4 LATIN AMERICA
                        TABLE 131 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
                        TABLE 132 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                        TABLE 133 LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 134 LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        TABLE 135 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                        TABLE 136 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                        TABLE 137 LATIN AMERICA: MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
                        TABLE 138 LATIN AMERICA: MARKET, BY END USER, 2020–2028 (USD MILLION)
                        11.1.4.1 Brazil
                                     11.1.4.1.1 Rising investments by leading transplant diagnostic manufacturers to favor market growth
                                                      TABLE 139 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 140 BRAZIL: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 141 BRAZIL: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.4.2 Mexico
                                     11.1.4.2.1 Rising medical tourism to support market growth
                                                      TABLE 142 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                                      TABLE 143 MEXICO: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                                      TABLE 144 MEXICO: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                        11.1.4.3 Rest of Latin America
                                      TABLE 145 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                      TABLE 146 REST OF LATIN AMERICA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                      TABLE 147 REST OF LATIN AMERICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
             11.1.5 MIDDLE EAST & AFRICA
                        11.1.5.1 Developing healthcare infrastructure to favor market growth
                                      TABLE 148 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2028 (USD MILLION)
                                      TABLE 149 MIDDLE EAST & AFRICA: MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                      TABLE 150 MIDDLE EAST & AFRICA: MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020–2028 (USD MILLION)
                                      TABLE 151 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2020–2028 (USD MILLION)
                                      TABLE 152 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                                      TABLE 153 MIDDLE EAST & AFRICA: MARKET, BY TRANSPLANT TYPE, 2020–2028 (USD MILLION)
                                      TABLE 154 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 176)
     12.1 INTRODUCTION 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
     12.3 MARKET SHARE ANALYSIS 
             FIGURE 31 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
     12.4 COMPETITIVE SCENARIO 
             12.4.1 PRODUCT LAUNCHES AND APPROVALS
             12.4.2 DEALS
     12.5 COMPETITIVE LEADERSHIP MAPPING 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 32 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
 
13 COMPANY PROFILES (Page No. - 183)
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 BIO-RAD LABORATORIES
                        TABLE 155 BIO-RAD LABORATORIES: COMPANY OVERVIEW (2021)
                        FIGURE 33 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
             13.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 156 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW (2021)
                        FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             13.1.3 QIAGEN NV
                        TABLE 157 QIAGEN NV: COMPANY OVERVIEW (2021)
                        FIGURE 35 QIAGEN NV: COMPANY SNAPSHOT (2021)
             13.1.4 BECTON, DICKINSON AND COMPANY
                        TABLE 158 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW (2021)
                        FIGURE 36 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.5 BIOFORTUNA
             13.1.6 BIOMÉRIEUX SA
                        TABLE 159 BIOMÉRIEUX SA: COMPANY OVERVIEW (2021)
                        FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             13.1.7 CAREDX
                        TABLE 160 CAREDX: COMPANY OVERVIEW (2021)
                        FIGURE 38 CAREDX: COMPANY SNAPSHOT (2021)
             13.1.8 GENDX
                        TABLE 161 GENDX: COMPANY OVERVIEW (2021)
             13.1.9 HOLOGIC, INC.
                        TABLE 162 HOLOGIC, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 39 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.10 ILLUMINA, INC.
                        TABLE 163 ILLUMINA, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
             13.1.11 IMMUCOR, INC.
                        TABLE 164 IMMUCOR, INC.: COMPANY OVERVIEW (2021)
                        FIGURE 41 IMMUCOR, INC.: COMPANY SNAPSHOT (2021)
             13.1.12 LUMINEX CORPORATION
                        TABLE 165 LUMINEX CORPORATION: COMPANY OVERVIEW (2021)
                        FIGURE 42 LUMINEX CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.13 MERCK KGAA
                        TABLE 166 MERCK KGAA: COMPANY OVERVIEW (2021)
                        FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021)
             13.1.14 OMIXON
                        TABLE 167 OMIXON: COMPANY OVERVIEW (2021)
             13.1.15 THERMO FISHER SCIENTIFIC
                        TABLE 168 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021)
                        FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
     13.2 OTHER PLAYERS 
             13.2.1 ALPHABIOTECH LIMITED
             13.2.2 BAG DIAGNOSTICS GMBH
             13.2.3 HANSA BIOPHARMA AB
             13.2.4 HISTOGENETICS LLC
             13.2.5 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
             13.2.6 TBG DIAGNOSTICS LIMITED
             13.2.7 TAKARA BIO INC.
             13.2.8 INNO-TRAIN DIAGNOSTIK GMBH
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 242)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microcatheter market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the medical aesthetic market. The primary sources from the demand side include medical OEMs, Oncologists, CDMOs and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Transplant Diagnostics Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the transplant diagnostic market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the transplant diagnostic business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • Generating a list of major global players operating in the transplant diagnostic market
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
  • Revenue mapping of major players to cover major share of the global market share, as of 2021
  • Extrapolating the global value of the transplant diagnostic market

Transplant Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approaches

Bottom-up Approach

  • For estimating the size of the transplant Diagnostics market, the country-level market revenues were obtained from secondary sources and through extensive primary interviews
  • Country-level markets for the US and Canada were added to arrive at the market size for North America. Similarly, country-level markets for other countries were added to arrive at the market size of Europe and Asia Pacific.
  • The total market derived through the bottom up approach was again validated through secondary sources and primaries.

Top-down approach

  • The overall market size derived from the bottom-up approach was used in the top-down procedure to estimate the size of the subsegment.
  • Percentage splits were applied to the total market size (splits were obtained from secondary and primary research) to obtain the market size for each subsegment.
  • The top-down approach was used to reach the regional and country-level market size for these subsegments.

Transplant Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the Transplant Diagnostic market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the transplant diagnostic market was validated using both top-down and bottom-up approaches.

Market definition

Transplant diagnostic procedures are used to determine donor-recipient compatibility to avoid immune rejection in a recipient. These procedures are adopted for donor-recipient cross-matching, subject profiling, genotyping and other related diagnostic tests. Advanced genomic techniques(such as PCR and NGS) are increasingly being used during transplant diagnostic procedures, apart from serological and other conventional techniques for immune-compatibility testing.

Key stakeholders

  • Transplant Diagnostic product manufacturing companies.
  • Healthcare service providers (Including hospitals, transplant centers and blood transfusion centers)
  • Blood, tissue and stem cell banks
  • Government Organizations
  • Independent association and regulatory authorities
  • R&D companies
  • Independent reference laboratories
  • Diagnostic Laboratories
  • Clinical Research organizations

Objectives of the Study

  • To define, describe, and forecast the Transplant diagnostic marketon the basis of Technology, Product & Service, Application,End User & Region.
  • To provide detailed information regarding the major factors influencing the growth potential of the  transplant diagnostic market(drivers, restraints, opportunities, challenges, and trends)
  • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the Transplant diagnostic market
  • To analyze key growth opportunities in the Transplant diagnostic market for key stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Thailand, Indonesia and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
  • To profile the key players in the Transplant diagnostic market and comprehensively analyze their market shares and core competencies
  • To track and analyze the competitive developments undertaken in the transplant diagnostic market, such as product launches; agreements; expansions; and mergers & acquisitions

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present transplant diagnostic market;

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe Transplant diagnostic marketinto Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of the Asia Pacific Transplant diagnostic marketinto Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Latin American Transplant diagnostic market into Colombia, Chile, Argentina, and Peru, among other
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4870
Published ON
Apr, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Transplant Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback